Open Interest and Volume Dynamics
On 7 January 2026, Lupin Ltd. recorded a substantial increase in open interest (OI) in its futures and options contracts. The latest OI stood at 27,548 contracts, up by 2,833 contracts or 11.46% from the previous figure of 24,715. This rise in OI was accompanied by a healthy trading volume of 50,717 contracts, indicating strong investor engagement in the derivatives market.
The futures segment alone accounted for a value of approximately ₹56,313.67 lakhs, while the options segment's notional value was significantly higher at ₹42,809.85 crores, culminating in a total derivatives market value of ₹63,847.93 lakhs. Such elevated activity underscores heightened speculative interest and hedging strategies among market participants.
Price Performance and Market Positioning
Lupin’s underlying stock price has mirrored this bullish sentiment, closing at ₹2,205 with an intraday high of ₹2,226.3, marking a 3.56% gain on the day. The stock outperformed its Pharmaceuticals & Biotechnology sector by 2.2% and the broader Sensex index, which declined by 0.30% on the same day. Over the past two trading sessions, Lupin has delivered a cumulative return of 6.16%, reflecting sustained buying interest.
Technical indicators further reinforce this positive momentum. The stock is trading above all key moving averages — 5-day, 20-day, 50-day, 100-day, and 200-day — signalling a strong uptrend. Additionally, delivery volumes surged to 14.65 lakh shares on 6 January, a remarkable 230.12% increase compared to the five-day average, highlighting rising investor participation in the cash market.
Market Capitalisation and Quality Metrics
Lupin Ltd. is classified as a large-cap stock with a market capitalisation of ₹1,00,557 crore. Its Market Cap Grade is rated 1, indicating top-tier market capitalisation within its sector. The company’s Mojo Score stands at 74.0, reflecting a robust overall quality and growth outlook. Notably, the Mojo Grade was upgraded from Hold to Buy on 12 November 2025, signalling improved fundamentals and positive market sentiment.
Perfect timing to enter! This Small Cap from IT - Software just turned profitable with growth momentum clearly building up. Get in before the broader market notices!
- - New profitability achieved
- - Growth momentum building
- - Under-the-radar entry
Interpreting the Open Interest Surge
The 11.46% increase in open interest, coupled with rising volumes, suggests that fresh positions are being established rather than existing ones being squared off. This typically indicates a strengthening trend, in this case, bullish given the concurrent price appreciation. Market participants appear to be positioning for further upside in Lupin’s shares, possibly anticipating positive developments in the pharmaceutical sector or company-specific catalysts.
Such a rise in OI often reflects increased hedging activity by institutional investors or speculative bets by traders expecting continued momentum. The substantial notional value in options contracts points to active call option buying, which aligns with a bullish outlook. Meanwhile, the futures market’s sizeable turnover confirms that participants are keen to leverage price movements in the underlying stock.
Sectoral and Broader Market Context
Within the Pharmaceuticals & Biotechnology sector, Lupin’s outperformance is notable. The sector’s 1-day return was 0.78%, significantly lower than Lupin’s 3.02% gain. This divergence highlights Lupin’s relative strength amid a mixed market environment. The Sensex’s marginal decline on the day further accentuates Lupin’s resilience and attractiveness to investors.
Pharmaceutical stocks have been under scrutiny due to regulatory developments and evolving global demand dynamics. Lupin’s ability to sustain gains and attract derivative market interest suggests confidence in its product pipeline, operational execution, and strategic initiatives.
Curious about Lupin Ltd. from Pharmaceuticals & Biotechnology? Get the complete picture with our detailed research report covering fundamentals, technicals, peer analysis, and everything you need to decide!
- - Detailed research coverage
- - Technical + fundamental view
- - Decision-ready insights
Investor Implications and Outlook
For investors, the surge in open interest and volume in Lupin’s derivatives signals a potential opportunity to capitalise on the stock’s upward trajectory. The upgrade in Mojo Grade to Buy, combined with strong technicals and rising delivery volumes, supports a constructive medium-term outlook.
However, investors should remain mindful of sector-specific risks such as regulatory changes, pricing pressures, and global supply chain challenges. While the current market positioning suggests bullish bets, prudent risk management and monitoring of evolving fundamentals remain essential.
Overall, Lupin Ltd.’s recent market activity reflects a growing consensus of strength, with increased participation from both retail and institutional players. The derivatives market data provides valuable insights into sentiment and positioning, reinforcing the stock’s appeal within the Pharmaceuticals & Biotechnology space.
Summary of Key Metrics
Lupin Ltd. currently trades at ₹2,205, with a market cap of ₹1,00,557 crore. The stock’s Mojo Score of 74.0 and upgraded Buy rating as of 12 November 2025 highlight its quality and growth potential. The open interest in derivatives rose by 11.46% to 27,548 contracts, supported by a volume of 50,717 contracts and a total derivatives market value exceeding ₹63,800 lakhs. Delivery volumes surged by over 230%, underscoring robust investor participation.
These factors collectively suggest that Lupin is well-positioned for further gains, backed by strong market interest and positive technical signals.
Upgrade at special rates, valid only for the next few days. Claim Your Special Rate →
